Morice sends us a message
Morice is his parents’ pride and joy. This two-year-old from the outskirts of Hanover, Germany, presents the classic X-linked form of CNM – a diagnosis that was reached only after a long and difficult journey. But instead of letting this devastating news get the better of them, Morice’s parents made a vow to never stop fighting for their son.
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.